TY - JOUR T1 - Effect of RBD (Y453F) mutation in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinity JF - medRxiv DO - 10.1101/2021.01.28.21250577 SP - 2021.01.28.21250577 AU - Takuma Hayashi AU - Nobuo Yaegashi AU - Ikuo Konishi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250577.abstract N2 - Background Infection with receptor binding domain (RBD) mutant (Y453F) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from farmed minks is known to widely spread among humans.Methods We investigated the characteristics of SARS-CoV-2 RBD Y453F mutant using three- dimensional structural analysis. We investigated the effect of the RBD Y453F mutant of SARS-CoV- 2 on neutralizing antibodies in serum derived from Corona virus Disease 2019 (COVID-19) positive patients.Results Our studies suggest that virus variants with RBD Y453F mutation partially escaped detection by four neutralizing monoclonal antibodies and neutralizing antibodies in serum.Conclusions Consequently, raising a concern that infection of SARS-CoV-2 mutants that cause serious symptoms in humans may spread globally.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Japan Ministry of Education, Culture, Science and Technology (No. 24592510, No. 15K1079, and No. 19K09840)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Central Ethics Review Board of the National Hospital Organization of Japan (Meguro, Tokyo, Japan). The approved number for this study is 50-201504. In order to carry out this research, the authors attended a research ethics education course (e-APRIN) conducted by Association for the Promotion of Research Integrity (APRIN; Shinjuku, Tokyo, Japan). The approved numbers of e-APRIN are AP0000151756, AP0000151757, AP0000151758, AP0000151769.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors shows all data referred to in the manuscript.AIDSacquired immunodeficiency syndromeCOVID-19coronavirus disease-2019HIVhuman immunodeficiency virusIgGimmunoglobulin GIgMimmunoglobulin MRBDreceptor binding domainSARS-CoV-2severe acute respiratory syndrome coronavirus-2UKUnited Kingdom ER -